Our deepest gratitude to all of our supporters including, U.S. Senator Charles E. Schumer who spoke at the event. “The Tisch MS Research Center is the ONLY place in the country with an FDA-approved Phase II stem cell clinical trial for MS,” said Senator Schumer. “The innovative research that Dr. Sadiq and his team do, brings us every day more hopeful... more


Catch up with Dr. Sadiq and his patient Aoife Kirwan as she interviews him about our recent advances in stem cell research at the 2017 ECTRIMS-ACTRIMS conference in Paris, France. Aoife lives in Ireland, and is an active blogger and advocate for patients with MS.

... more


The IMSMP would like to thank everyone who attended the 2017 Tisch MSRCNY Patient Symposium and helped make it a success. Please take a moment and share your thoughts with us. 



Oct. 25th-28th, 2017 – Tisch MSRCNY researchers travel to Paris, France to attend the 2017 joint ECTRIMS-ACTRIMS meeting.

This week, five of Tisch MSRCNY’s researchers are in Paris, France to attend the 7th ever joint ECTRIMS-ACTRIMS meeting. Eight abstracts from our Tisch MSRCNY researchers will... more


The IMSMP wishes everyone celebrating Rosh Hashanah with their family and friends, a meaningful new year. May the coming year be filled with health and happiness.


Tisch MS Research Center of New York (Tisch MSRCNY) will hold its' 20th Annual MS Patient Education Symposium on Sunday, October 22nd at the New York Hilton in Midtown. The doors open at 8:30am and the program will be from 9:30am to 1:00pm.

To register please visit:

We are... more


This letter is to inform you that as of August 31, 2017, Dr. Andrew Sylvester will no longer be a provider at the International Multiple Sclerosis Management Practice. Dr. Sylvester and the IMSMP are currently working to ensure that you continue to receive the same level of care, without disruption.

You, as the patient, have two options going forward:

1. Dr. Sylvester will become the new Medical Director of the Multiple Sclerosis Comprehensive Care Center at St. Barnabas Health... more


We are thrilled to announce, Dr. Saud A. Sadiq is a, New York Magazine, Best Doctor in the field of Neurology for 2017. Of the 40 neurologists selected for this prestigious recognition, Dr. Saud A. Sadiq is the only physician listed who specializes in multiple sclerosis.

To view Dr. Saud A. Sadiq's full bio, Click Here.

To view New York Magazine's Best Doctor's list,... more


What's the Latest in the Pipeline for MS Drugs that Might Help?

"Whether you’ve just been diagnosed with multiple sclerosis or you’ve been dealing with your symptoms for years, it’s in your best interest to keep on top of the latest advances in medications. The good news is there are plenty of drugs being tested, and hopefully many will get through the regulatory pipeline to help patients cope with their MS. . ."

... more


Ocrelizumab (OCREVUS™), an anti-B cell therapy has been approved by the FDA as of March 28th 2017, for the treatment of Relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). This treatment is highly effective for RRMS, based on the data from the Phase III clinical studies. It is also the first drug approved for use in PPMS. At IMSMP/TISCH we have used Rituximab, a similar anti-B cell treatment, for the past 16 years with great success. It is because... more



Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.